Introduction

• JOINSTAR's Alzheimer's Disease Solution provides core biomarker testing including Aβ1-42, Aβ1-40, p-Tau-181, p-Tau-217, GFAP, and NFL, achieving high-sensitivity precise detection based on the iMatrix liquid chip platform and CLIA platform.

Clinical Applications

• Alzheimer's disease core biomarker testing enables early screening and precise diagnosis of the disease.
• Neurology Department: Early diagnosis and differential diagnosis of Alzheimer's disease in patients with cognitive impairment.
• Geriatrics Department: Risk assessment and early screening for cognitive decline in elderly populations.
• Health Check-up Centers: Neurodegenerative disease screening for high-risk Alzheimer's populations.
• Research Institutions: Efficacy evaluation in Alzheimer's drug clinical trials and biomarker monitoring.